Although there is no convincing evidence showing the efficacy of low dose COX inhibitors in the therapy of DN, the combination of a lower dose COX inhibitor with SPPARγM or endogenous PPARγ agonist could be a feasible strategy in treating DN. The gene discussed is PPARG; the disease is liver dysplastic nodule.